India.com News Desk | Sep 16, 2020, 8:11 AM IST
The DCGI has advised taking extra care during screening, providing additional information in informed consent and close monitoring for adverse events during follow-up of the study which have to be "scrupulously" followed by the SII.
India.com News Desk | Sep 13, 2020, 12:05 AM IST
Clinical trials for the AstraZeneca Oxford Coronavirus vaccine, AZD1222, have resumed in the UK following confirmation by the Medicines Health Regulatory Authority (MHRA) that it was safe to do so.
India.com News Desk | Sep 9, 2020, 9:52 PM IST
The DGCI also sent the notice to SII for not informing it about AstraZeneca pausing the clinical trials of the Oxford vaccine candidate for COVID-19 in other countries and also for not submitting casualty analysis of the "reported serious adverse events".
India.com News Desk | Sep 9, 2020, 5:06 PM IST
Serum Institute of India CEO Adar Poonawalla said AstraZeneca has paused the trial for further review and will restart soon.
India.com News Desk | Aug 30, 2020, 5:24 PM IST
"The investment amount will be treated as an advance and once the vaccine receives regulatory approvals, SII will include Bangladesh among the countries who will be the first to receive an agreed quantity of this vaccine from SII on a priority basis," the news agency quoted Beximco as saying in a statement.
India.com News Desk | Aug 12, 2020, 1:58 PM IST
The Serum Institute has said it has entered into a new partnership with international vaccine alliance Gavi and Bill & Melinda Gates Foundation to accelerate manufacturing and delivery of up to 100 million doses of vaccines for India and other low and middle-income countries.
India.com News Desk | Aug 10, 2020, 7:40 PM IST
The Serum Institute had earlier said that the coronavirus vaccine will be available at less than Rs 250 per dose in India.
IANS | Aug 7, 2020, 6:28 PM IST
As per SII, the vaccines will be available as early as the first half of 2021 after gaining approvals and qualifications from the World Health Organization (WHO).
India.com News Desk | Aug 7, 2020, 5:41 PM IST
Earlier this week, the Drugs Controller General of India (DCGI) approved Serum Institute's permission to conduct clinical trials of Oxford University-Astra Zeneca COVID-19 vaccine in India.
India.com News Desk | Aug 1, 2020, 8:22 AM IST
About 1,600 people aged above 18 will participate in the trials across 17 selected sites, including AIIMS Delhi, BJ Medical College, Pune, Rajendra Memorial Research Institute of Medical Sciences (RMRIMS) Patna etc
India.com News Desk | Jul 28, 2020, 8:43 AM IST
Serum Institute, the world's largest vaccine manufacturer, was chosen by Oxford University as the manufacturing partner for its COVID-19 vaccine candidate after it cleared the first phase of human trials.
PTI | Jul 21, 2020, 11:22 PM IST
Oxford University on Monday announced satisfactory progress with the vaccine, making it one of the leading ones among the dozens of vaccine candidates being developed around the world.
